Cefsar-CV

Cefsar-CV Tablet is a powerful broad-spectrum antibiotic formulation from Amista Labs, developed to combat a wide range of bacterial infections effectively and safely. It is a combination of Cefpodoxime IP 200mg, a third-generation cephalosporin antibiotic, and Clavulanic Acid IP 125mg, a beta-lactamase inhibitor. This dual-action composition enhances antibacterial efficacy and helps overcome bacterial resistance, making it a trusted choice for physicians.

Composition and Pharmacokinetics

Each tablet of Cefsar-CV contains:

• Cefpodoxime Proxetil IP: Equivalent to Cefpodoxime 200 mg
• Potassium Clavulanate IP: Equivalent to Clavulanic Acid 125 mg

Mechanism of Action

1. Cefpodoxime Proxetil: This is a bactericidal antibiotic. It works by inhibiting the synthesis of the bacterial cell wall. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, which prevents the final step of cell wall assembly. Without a stable cell wall, the bacteria undergo osmotic lysis and die.
2. Clavulanic Acid: Many bacteria produce enzymes called beta-lactamases that can deactivate cephalosporins, leading to antibiotic resistance. Clavulanic acid is a “suicide inhibitor” that binds to these enzymes, neutralizing them. This protects the Cefpodoxime from degradation, allowing it to effectively eliminate the infection.

Clinical Indications

Cefsar-CV is indicated for the treatment of various mild to moderate infections caused by susceptible strains of microorganisms:

• Respiratory Tract Infections: Highly effective for Upper Respiratory Tract Infections (URTI) like Sinusitis and Tonsillitis, as well as Lower Respiratory Tract Infections (LRTI) like Acute Bronchitis and community-acquired Pneumonia.
• Urinary Tract Infections (UTIs): Indicated for both complicated and uncomplicated UTIs, including cystitis and pyelonephritis.
• Skin and Soft Tissue Infections: Used to treat cellulitis, abscesses, and infected wounds where beta-lactamase producing bacteria are suspected.
• Switch Therapy: Often used as a step-down or “switch” therapy for patients transitioning from intravenous to oral antibiotic treatment.

Manufacturing Standards and Quality Assurance

Amista Labs ensures that Cefsar-CV is produced under stringent global quality benchmarks:

• WHO-GMP Certified: The manufacturing process adheres strictly to World Health Organization – Good Manufacturing Practices.
• GLP (Good Laboratory Practice): Every batch undergoes rigorous laboratory testing to ensure purity, potency, and stability.
• ISO 9001:2015: The management and quality control systems are ISO certified, guaranteeing consistent product excellence.

Dosage and Administration

Cefsar-CV is typically administered twice daily (every 12 hours) with food to enhance absorption. The duration of the course usually ranges from 5 to 14 days depending on the severity of the infection. It is critical that patients complete the full course of treatment to prevent the development of antibiotic resistance.

Commercial Details

• Brand Name: Cefsar-CV
• Company: AMISTA LABS
• MRP: ₹ 3281.25/- per Box
• Packing: 10x1x10 (Alu-Alu blister packing to ensure protection against moisture and light)
• Category: Antibiotic / Antibacterial

Safety Profile

While generally well-tolerated, some patients may experience mild side effects such as nausea, diarrhea, or abdominal pain. It is contraindicated in patients with a known hypersensitivity to cephalosporins or penicillins. Due to the presence of Clavulanic Acid, patients with a history of cholestatic jaundice or hepatic dysfunction should use this medication with caution.

About the Company

Amista Labs is a pharmaceutical organization dedicated to providing high-quality healthcare solutions. With a motto of “In Quest of Better Health,” the company focuses on innovation and accessibility. Based in India, they maintain a robust digital presence through their website (www.amistalabs.org) and provide dedicated support via multiple contact channels.